In the analysis of immunoinhibitors, SMARCD3 showed a positive correlation with LGALS9 and C10orf54 in PRAD, was positively correlated with TGFβ1 in READ, and demonstrated a negative correlation with CD274 and BTLA in MESO and UCS, respectively. The gene discussed is CD274; the disease is prostate adenocarcinoma.